DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
drugmaker - 1 Indivior - 1 Suboxone - 1 Josh Kaul - 1 Mariam Sunny - 1 Jonathan Stempel - 1 Maju Samuel - 1 Matthew Lewis - 1
Top related locs:
Chesterfield , Virginia U.S Washington Indivior's Philadelphia Suboxone Wisconsin United States
Top related orgs:
Indivior - 1 D.C - 1 U.S - 1 U.S . Centers for Disease Control - 1 Thomson - 1

Search resuls for: "Indivior's"


2 mentions found


☆ US drugmaker Indivior to pay $102.5 million to settle Suboxone monopoly claims
  + stars: | 2023-06-02 | by ( Jonathan Stempel Mariam E Sunny | Jonathan Stempel | Mariam E Sunny | ) www.reuters.com   time to read: +2 min
Companies Indivior PLC FollowJune 2 (Reuters) - Indivior Plc (INDV.L) said on Friday it agreed to pay $102.5 million to settle a lawsuit by dozens of U.S. states accusing it of illegally suppressing generic competition for its opioid addiction treatment Suboxone. Suboxone was approved for U.S. sale in 2002, and Indivior had the exclusive right to sell the treatment in tablet form until 2009. States said Indivior switched to an oral film version of Suboxone from a tablet version to extend its monopoly, just as generic manufacturers were poised to sell their own lower-cost tablets. Generic tablets obtained federal approval in 2013. Indivior expects to pay the $102.5 million in cash this month.
Persons: drugmaker, Indivior, Suboxone, Josh Kaul, Mariam Sunny, Jonathan Stempel, Maju Samuel, Matthew Lewis Organizations: Indivior, D.C, U.S, U.S . Centers for Disease Control, Thomson Locations: Chesterfield , Virginia, U.S, Washington, Indivior's, Philadelphia, Suboxone, Wisconsin, United States, Bengaluru, New York
☆ Warren tells FTC she is "particularly concerned" about Amgen and Indivior deals
  + stars: | 2023-01-26 | by ( ) www.reuters.com   time to read: +2 min
Warren said that both Amgen and Horizon Therapeutics "have engaged in brazen price increases," including on Amgen's Enbrel for arthritis and Horizon’s Krystexxa, a gout medication. She noted that the FTC had settled with Indivior and its former parent over its attempt to protect its monopoly of the opioid addiction treatment Suboxone. Indivior makes Sublocade -- a slow-release treatment for opioid addiction that is administered monthly. "The FTC should strongly consider Indivior's history of anti-competitive and deceptive practices when evaluating howIndivior might behave after this potential transaction is completed," wrote Warren. Warren noted that the FTC, which has long focused on healthcare mergers, said in 2021 that it would prioritize pharmaceutical acquisitions.
0 next >>
Total: 2